Notable
THT-CMM · Intratumoral Targeted Hyperthermia Therapy (THT) for Stage 3C/3D/4M1 Cutaneous Metastatic Melanoma
Primary endpoint(s) modified
Also in this update: Completed without a posted recruiting period; Primary completion date changed from estimate of Apr 2026 to Sep 26, 2025
Sona Nanotech IncNot applicable NCT06894407 Registry history of NCT06894407 on ClinicalTrials.gov (opens the registry)